A detailed history of Sectoral Asset Management Inc transactions in Argenx Se stock. As of the latest transaction made, Sectoral Asset Management Inc holds 3,997 shares of ARGX stock, worth $2.26 Million. This represents 1.81% of its overall portfolio holdings.

Number of Shares
3,997
Previous 6,522 38.72%
Holding current value
$2.26 Million
Previous $2.8 Million 22.72%
% of portfolio
1.81%
Previous 1.39%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$434.22 - $551.9 $1.1 Million - $1.39 Million
-2,525 Reduced 38.72%
3,997 $2.17 Million
Q2 2024

Aug 13, 2024

SELL
$356.01 - $451.55 $991,487 - $1.26 Million
-2,785 Reduced 29.92%
6,522 $2.8 Million
Q1 2024

May 14, 2024

SELL
$356.95 - $413.29 $257,004 - $297,568
-720 Reduced 7.18%
9,307 $3.66 Million
Q4 2023

Feb 14, 2024

BUY
$338.91 - $506.01 $2.98 Million - $4.45 Million
8,800 Added 717.2%
10,027 $3.81 Million
Q3 2023

Nov 14, 2023

BUY
$369.35 - $548.43 $63,897 - $94,878
173 Added 16.41%
1,227 $603,000
Q2 2023

Aug 11, 2023

BUY
$360.14 - $422.58 $73,468 - $86,206
204 Added 24.0%
1,054 $410,000
Q1 2023

May 12, 2023

SELL
$334.23 - $403.65 $26,738 - $32,292
-80 Reduced 8.6%
850 $316,000
Q4 2022

Feb 10, 2023

SELL
$342.17 - $402.31 $116,337 - $136,785
-340 Reduced 26.77%
930 $352,000
Q2 2022

Aug 15, 2022

BUY
$269.58 - $378.88 $342,366 - $481,177
1,270 New
1,270 $481,000
Q4 2021

Feb 11, 2022

SELL
$272.01 - $353.03 $427,055 - $554,257
-1,570 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$295.0 - $350.58 $88,500 - $105,174
-300 Reduced 16.04%
1,570 $474,000
Q1 2021

May 14, 2021

SELL
$268.3 - $380.31 $169,029 - $239,595
-630 Reduced 25.2%
1,870 $515,000
Q2 2020

Aug 13, 2020

BUY
$127.44 - $232.72 $318,600 - $581,800
2,500 New
2,500 $563,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Sectoral Asset Management Inc Portfolio

Follow Sectoral Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sectoral Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Sectoral Asset Management Inc with notifications on news.